|
GOG Trial
|
N
|
ORR
|
PFS > 6mo
|
Median PFS (mo.)
|
Median OS (mo.)
|
|---|
|
229 N [7]
|
28
|
0 %
|
11 %
|
2.1
|
9.4
|
|
229 K [6]
|
37
|
9.4 %
|
22 %
|
3.3
|
10.1
|
|
229 I [8]
|
45
|
18.6 %
|
30 %
|
3.3
|
10.7
|
|
229 G* [5]
|
53
|
24.5 %
|
47 %
|
5.6
|
16.9
|
|
229 F* [4]
|
49
|
8.9 %
|
40 %
|
2.9
|
14.6
|
|
229 E [3]
|
56
|
13.5 %
|
40.4 %
|
4.2
|
10.5
|
|
229 J [9]
|
53
|
12.5 %
|
29 %
|
3.5
|
12.5
|
- *Significant Grade 3/4 adverse events were encountered on these studies preventing subsequent development of a phase 3 trial; GOG = gynecologic oncology group; ORR = overall response rate; PFS = progression free survival; OS = overall survival
